Literature DB >> 11564799

Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands.

K E de Visser1, T A Cordaro, H W Kessels, F H Tirion, T N Schumacher, A M Kruisbeek.   

Abstract

Thymic expression of self-Ags results in the deletion of high-avidity self-specific T cells, but, at least for certain Ags, a residual population of self-specific T cells with low-affinity TCRs remains after negative selection. Such self-specific T cells are thought to play a role in the induction of T cell-mediated autoimmunity, but may also be used for the induction of antitumor immunity against self-Ags. In this study, we examine the functional competence of a polyclonal population of self-specific CD8+ T cells. We show that low-affinity interactions between TCR and peptide are associated with selective loss of critical T cell functions. Triggering of low levels of IFN-gamma production and cytolytic activity through low-affinity TCRs readily occurs provided high Ag doses are used, but IL-2 production and clonal expansion are severely reduced at all Ag doses. Remarkably, a single peptide variant can form an improved ligand for the highly diverse population of low-avidity self-specific T cells and can improve their proliferative capacity. These data provide insight into the inherent limitations of self-specific T cell responses through low-avidity TCR signals and the effect of modified peptide ligands on self-specific T cell immunity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564799     DOI: 10.4049/jimmunol.167.7.3818

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

Authors:  Willem W Overwijk; Karin E de Visser; Felicia H Tirion; Laurina A de Jong; Thijs W H Pols; Yme U van der Velden; Jasper G van den Boorn; Anna M Keller; Wim A Buurman; Marc R Theoret; Bianca Blom; Nicholas P Restifo; Ada M Kruisbeek; Robert A Kastelein; John B A G Haanen
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

2.  Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f 1 allergy.

Authors:  Anu K Immonen; Antti H Taivainen; Ale T O Närvänen; Tuure T Kinnunen; Soili A Saarelainen; Marja A Rytkönen-Nissinen; Tuomas I Virtanen
Journal:  Immunology       Date:  2007-01       Impact factor: 7.397

Review 3.  Translating tumor antigens into cancer vaccines.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

Review 4.  Improving T cell responses to modified peptides in tumor vaccines.

Authors:  Jonathan D Buhrman; Jill E Slansky
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

5.  Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses.

Authors:  Charles B Kemmler; Eric T Clambey; Ross M Kedl; Jill E Slansky
Journal:  J Immunol       Date:  2011-09-21       Impact factor: 5.422

6.  Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines.

Authors:  Rachel H McMahan; Jennifer A McWilliams; Kimberly R Jordan; Steven W Dow; Darcy B Wilson; Jill E Slansky
Journal:  J Clin Invest       Date:  2006-08-24       Impact factor: 14.808

7.  Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.

Authors:  Jonathan D Buhrman; Kimberly R Jordan; Lance U'ren; Jonathan Sprague; Charles B Kemmler; Jill E Slansky
Journal:  Cancer Res       Date:  2012-11-16       Impact factor: 12.701

Review 8.  Peptide vaccines for hematological malignancies: a missed promise?

Authors:  Monica Bocchia; Marzia Defina; Lara Aprile; Anna Sicuranza
Journal:  Int J Hematol       Date:  2014-01-08       Impact factor: 2.490

Review 9.  Mobilizing the low-avidity T cell repertoire to kill tumors.

Authors:  Rachel H McMahan; Jill E Slansky
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

Review 10.  Immune tolerance to myelin proteins.

Authors:  Audrey Seamons; Antoine Perchellet; Joan Goverman
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.